Evidence map›Paper›PMID 39809981›Full record

SynthesisScientific reports2025

The impact of metabolic syndrome on hepatocellular carcinoma: a mendelian randomization study.

Chendong Yuan, Xufeng Shu, Xiaoqiang Wang, Wenzheng Chen, Xin Li, Wenguang Pei, Xujie Su, Zhenzhen Hu, Zhigang Jie

Abstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Chendong Yuan *Medical Innovation Center, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 17, Yongwai Main Street, Nanchang, 330006, Jiangxi, China.
Xufeng Shu *Medical Innovation Center, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 17, Yongwai Main Street, Nanchang, 330006, Jiangxi, China.
Xiaoqiang Wang *Medical Innovation Center, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 17, Yongwai Main Street, Nanchang, 330006, Jiangxi, China.
Wenzheng ChenMedical Innovation Center, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 17, Yongwai Main Street, Nanchang, 330006, Jiangxi, China.
Xin LiDepartment of Gastroenterology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, Jiangxi, China.
Wenguang PeiMedical Innovation Center, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 17, Yongwai Main Street, Nanchang, 330006, Jiangxi, China.
Xujie SuMedical Innovation Center, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 17, Yongwai Main Street, Nanchang, 330006, Jiangxi, China.
Zhenzhen HuDepartment of Anesthesiology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 17, Yongwai Main Street, Nanchang, 330006, Jiangxi, China. ndyfyhzz9989@163.com.
Zhigang JieMedical Innovation Center, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 17, Yongwai Main Street, Nanchang, 330006, Jiangxi, China. ndyfy00524@ncu.edu.cn.

Funding

Jiangxi Provincial Health Technology Project No. 202310020the First Affiliated Hospital of Nanchang University Young Talent Research and Cultivation Project No. YFYPY202272
6 · The paper itself

Abstract

Traditional epidemiological studies are susceptible to confounding factors. To clarify the impact of metabolic syndrome and its diagnostic components on hepatocellular carcinoma, we conducted a preliminary mendelian randomization analysis with metabolic syndrome and its diagnostic components as exposures and hepatocellular carcinoma as the outcome. Another set of genetic data related to hepatocellular carcinoma was used as a validation cohort, repeating the mendelian randomization analysis and combining the two groups for a meta-analysis. Preliminary analysis showed that metabolic syndrome (P-value = 0.002) and waist circumference (P-value = 0.026) are significantly positively correlated with an increased risk of hepatocellular carcinoma. After multiple testing corrections, metabolic syndrome (P

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsMendelian Randomization AnalysisMetabolic SyndromeHumansMaleRisk FactorsWaist CircumferenceHepatocellular carcinomaMendelian randomizationMetabolic syndromeWaist circumference

Identifiers

PMID39809981
PMCPMC11733230

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.